Literature DB >> 1618758

Role of the antithrombin-binding pentasaccharide in heparin acceleration of antithrombin-proteinase reactions. Resolution of the antithrombin conformational change contribution to heparin rate enhancement.

S T Olson1, I Björk, R Sheffer, P A Craig, J D Shore, J Choay.   

Abstract

The synthetic antithrombin-binding heparin pentasaccharide and a full-length heparin of approximately 26 saccharides containing this specific sequence have been compared with respect to their interactions with antithrombin and their ability to promote inhibition and substrate reactions of antithrombin with thrombin and factor Xa. The aim of these studies was to elucidate the pentasaccharide contribution to heparin's accelerating effect on antithrombin-proteinase reactions. Pentasaccharide and full-length heparins bound antithrombin with comparable high affinities (KD values of 36 +/- 11 and 10 +/- 3 nM, respectively, at I 0.15) and induced highly similar protein fluorescence, ultraviolet and circular dichroism changes in the inhibitor. Stopped-flow fluorescence kinetic studies of the heparin binding interactions at I 0.15 were consistent with a two-step binding process for both heparins, involving an initial weak encounter complex interaction formed with similar affinities (KD 20-30 microM), followed by an inhibitor conformational change with indistinguishable forward rate constants of 520-700 s-1 but dissimilar reverse rate constants of approximately 1 s-1 for the pentasaccharide and approximately 0.2 s-1 for the full-length heparin. Second order rate constants for antithrombin reactions with thrombin and factor Xa were maximally enhanced by the pentasaccharide only 1.7-fold for thrombin, but a substantial 270-fold for factor Xa, in an ionic strength-independent manner at saturating oligosaccharide. In contrast, the full-length heparin produced large ionic strength-dependent enhancements in second order rate constants for both antithrombin reactions of 4,300-fold for thrombin and 580-fold for factor Xa at I 0.15. These enhancements were resolvable into a nonionic component ascribable to the pentasaccharide and an ionic component responsible for the additional rate increase of the larger heparin. Stoichiometric titrations of thrombin and factor Xa inactivation by antithrombin, as well as sodium dodecyl sulfate-polyacrylamide gel electrophoresis of the products of these reactions, indicated that pentasaccharide and full-length heparins similarly promoted the formation of proteolytically modified inhibitor during the inactivation of factor Xa by antithrombin, whereas only the full-length heparin was effective in promoting this substrate reaction of antithrombin during the reaction with thrombin.(ABSTRACT TRUNCATED AT 400 WORDS)

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1618758

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  102 in total

1.  Anti-thrombin is expressed in the benign prostatic epithelium and in prostate cancer and is capable of forming complexes with prostate-specific antigen and human glandular kallikrein 2.

Authors:  Yue Cao; Ake Lundwall; Virgil Gadaleanu; Hans Lilja; Anders Bjartell
Journal:  Am J Pathol       Date:  2002-12       Impact factor: 4.307

2.  Pentosan polysulfate increases affinity between ADAMTS-5 and TIMP-3 through formation of an electrostatically driven trimolecular complex.

Authors:  Linda Troeberg; Barbara Mulloy; Peter Ghosh; Meng-Huee Lee; Gillian Murphy; Hideaki Nagase
Journal:  Biochem J       Date:  2012-04-01       Impact factor: 3.857

3.  Specificity and selectivity profile of EP217609: a new neutralizable dual-action anticoagulant that targets thrombin and factor Xa.

Authors:  Steven T Olson; Richard Swanson; Maurice Petitou
Journal:  Blood       Date:  2011-12-05       Impact factor: 22.113

Review 4.  Limitations of conventional anticoagulant therapy and the promises of non-heparin based conformational activators of antithrombin.

Authors:  Qudsia Rashid; Poonam Singh; Mohammad Abid; Mohamad Aman Jairajpuri
Journal:  J Thromb Thrombolysis       Date:  2012-08       Impact factor: 2.300

5.  Characterization of a heparin-binding site on the catalytic domain of factor XIa: mechanism of heparin acceleration of factor XIa inhibition by the serpins antithrombin and C1-inhibitor.

Authors:  Likui Yang; Mao-fu Sun; David Gailani; Alireza R Rezaie
Journal:  Biochemistry       Date:  2009-02-24       Impact factor: 3.162

6.  Initial experience with recombinant antithrombin to treat antithrombin deficiency in patients on extracorporeal membrane oxygenation.

Authors:  Kevin S Niimi; Jeffrey J Fanning
Journal:  J Extra Corpor Technol       Date:  2014-03

7.  Engineering D-helix of antithrombin in alpha-1-proteinase inhibitor confers antiinflammatory properties on the chimeric serpin.

Authors:  L Yang; P Dinarvand; S H Qureshi; A R Rezaie
Journal:  Thromb Haemost       Date:  2014-02-13       Impact factor: 5.249

8.  Identification of factor Xa residues critical for interaction with protein Z-dependent protease inhibitor: both active site and exosite interactions are required for inhibition.

Authors:  Alireza R Rezaie; Chandrashekhara Manithody; Likui Yang
Journal:  J Biol Chem       Date:  2005-08-03       Impact factor: 5.157

Review 9.  Novel antithrombotic drugs in development.

Authors:  M Verstraete; P Zoldhelyi
Journal:  Drugs       Date:  1995-06       Impact factor: 9.546

10.  Elimination of glycosylation heterogeneity affecting heparin affinity of recombinant human antithrombin III by expression of a beta-like variant in baculovirus-infected insect cells.

Authors:  E Ersdal-Badju; A Lu; X Peng; V Picard; P Zendehrouh; B Turk; I Björk; S T Olson; S C Bock
Journal:  Biochem J       Date:  1995-08-15       Impact factor: 3.857

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.